Milestone Pharmaceuticals (MIST) Total Non-Current Liabilities (2020 - 2026)

Milestone Pharmaceuticals (MIST) has 7 years of Total Non-Current Liabilities data on file, last reported at $102.0 million in Q1 2026.

• Quarterly Total Non-Current Liabilities rose 583.34% year-over-year to $102.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $102.0 million (up 583.34% YoY) and the FY2025 annual result came in at $71.7 million, up 673.06% from the prior year.
• Total Non-Current Liabilities grew to $102.0 million in Q1 2026, from $71.7 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $102.0 million in Q1 2026 to a low of -$48.3 million in Q2 2022.
• A 5-year average of $6.2 million and a median of $8.7 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2024 — Total Non-Current Liabilities plunged 65.42% — and 2025, when it soared 673.06%.
• Tracing MIST's Total Non-Current Liabilities over 5 years: stood at -$26.2 million in 2022, then surged by 138.13% to $10.0 million in 2023, then dropped by 7.2% to $9.3 million in 2024, then soared by 673.06% to $71.7 million in 2025, then surged by 42.29% to $102.0 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $102.0 million (Q1 2026), $71.7 million (Q4 2025), and $11.6 million (Q3 2025), per Business Quant data.